Abstract： Teduglutide (TED), an analog of intestinotrophic hormone glucagon-like-peptide 2 (GLP-2), may facilitate intestinal nutrient transport, boost intestinal blood flow, promote the proliferation of crypt cells, arrest apoptosis of crypt cells and enhance intestinal barrier function. After dosing TED in adults with short bowel syndrome (SBS), duration/dose of parenteral nutrition (PN) declined. This review summarizes the mechanisms of GLP-2 and TED, as well as the effectiveness and safety of TED for pediatric SBS to provide rationales for domestic researches.